Linked e-resources
Details
Table of Contents
Intro; Dedication; Foreword; Preface; Contents; Contributors; About the Editor; Part I: Parasitic Infections; Chapter 1: Satranidazole and My Pharmaceutical Research Odyssey: A Success Story; References; Chapter 2: Amoebiasis Revisited; 2.1 Historical Background; 2.2 Introduction; 2.3 Epidemiology; 2.4 E. histolytica: Structure and Life Cycle; 2.5 Symptoms and Clinical Diagnosis; 2.6 Treatment; 2.7 Preventive Measures; 2.8 Antiamoebic Drugs; 2.9 The Perspective; References; Chapter 3: Cerebral Malaria: Players in the Pathogenic Mechanism and Treatment Strategies; 3.1 Introduction
3.2 The Burden of Cerebral Malaria3.3 The Clinical Syndrome "Cerebral Malaria"; 3.4 Pathophysiology of Cerebral Malaria; 3.4.1 Sequestration Hypothesis; 3.4.2 Inflammation Hypothesis; 3.5 Players in the Pathogenesis of Cerebral Malaria; 3.5.1 Blood-Brain Barrier and Parasitized RBCs; 3.5.2 Cell Adhesion Receptors; 3.5.3 Monocytes/Macrophages; 3.5.4 Cytokines; 3.6 Diagnosis of Cerebral Malaria; 3.7 Treatment of Cerebral Malaria; 3.7.1 Antimalarial Treatment; 3.8 Adjunct Therapy for Cerebral Malaria Treatment; 3.9 Immunomodulators; 3.9.1 Corticosteroids; 3.9.2 Intravenous Immunoglobulin
4.4 Diagnosis of the Disease4.5 Mechanism of Cerebral Malaria; 4.6 Murine Model of Cerebral Malaria; 4.7 Role of Adhesion Molecules in Cerebral Malaria; 4.8 T Helper and T Cytotoxic Cells; 4.9 Monocytes/Macrophages and Dendritic Cells; 4.10 T Regulatory Cells (Tregs); 4.11 Natural Killer (NK) Cells; 4.12 Blood-Brain Barrier (BBB); 4.13 Concluding Remarks; References; Chapter 5: Chemotherapy and Experimental Models of Visceral Leishmaniasis; 5.1 Introduction; 5.2 Life Cycle of Leishmania Parasite; 5.3 The Life Cycle of Leishmania Parasite in Vector
5.4 Factors Influencing Leishmaniasis Infection5.4.1 Environmental and Socio-economic Status; 5.4.2 Drug Resistance, a Serious Obstacle for Leishmaniasis Treatment; 5.4.3 Nonavailability of a Proper Vaccine(s); 5.5 Development of Drugs for Co-infections; 5.5.1 HIV-VL Co-infection; 5.5.2 Malaria-VL Co-infections; 5.6 Diagnosis of VL; 5.6.1 Microscopic Detection of Parasite; 5.6.2 Haematological Examination; 5.6.3 Indirect Fluorescent Antibody Test (IFAT); 5.7 Biomarkers for VL; 5.7.1 Direct Markers; 5.7.2 Indirect Markers; 5.8 Current Chemotherapeutic Agents for VL
3.2 The Burden of Cerebral Malaria3.3 The Clinical Syndrome "Cerebral Malaria"; 3.4 Pathophysiology of Cerebral Malaria; 3.4.1 Sequestration Hypothesis; 3.4.2 Inflammation Hypothesis; 3.5 Players in the Pathogenesis of Cerebral Malaria; 3.5.1 Blood-Brain Barrier and Parasitized RBCs; 3.5.2 Cell Adhesion Receptors; 3.5.3 Monocytes/Macrophages; 3.5.4 Cytokines; 3.6 Diagnosis of Cerebral Malaria; 3.7 Treatment of Cerebral Malaria; 3.7.1 Antimalarial Treatment; 3.8 Adjunct Therapy for Cerebral Malaria Treatment; 3.9 Immunomodulators; 3.9.1 Corticosteroids; 3.9.2 Intravenous Immunoglobulin
4.4 Diagnosis of the Disease4.5 Mechanism of Cerebral Malaria; 4.6 Murine Model of Cerebral Malaria; 4.7 Role of Adhesion Molecules in Cerebral Malaria; 4.8 T Helper and T Cytotoxic Cells; 4.9 Monocytes/Macrophages and Dendritic Cells; 4.10 T Regulatory Cells (Tregs); 4.11 Natural Killer (NK) Cells; 4.12 Blood-Brain Barrier (BBB); 4.13 Concluding Remarks; References; Chapter 5: Chemotherapy and Experimental Models of Visceral Leishmaniasis; 5.1 Introduction; 5.2 Life Cycle of Leishmania Parasite; 5.3 The Life Cycle of Leishmania Parasite in Vector
5.4 Factors Influencing Leishmaniasis Infection5.4.1 Environmental and Socio-economic Status; 5.4.2 Drug Resistance, a Serious Obstacle for Leishmaniasis Treatment; 5.4.3 Nonavailability of a Proper Vaccine(s); 5.5 Development of Drugs for Co-infections; 5.5.1 HIV-VL Co-infection; 5.5.2 Malaria-VL Co-infections; 5.6 Diagnosis of VL; 5.6.1 Microscopic Detection of Parasite; 5.6.2 Haematological Examination; 5.6.3 Indirect Fluorescent Antibody Test (IFAT); 5.7 Biomarkers for VL; 5.7.1 Direct Markers; 5.7.2 Indirect Markers; 5.8 Current Chemotherapeutic Agents for VL